Connection

EVELINE BARBIERI to Xenograft Model Antitumor Assays

This is a "connection" page, showing publications EVELINE BARBIERI has written about Xenograft Model Antitumor Assays.
  1. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clin Cancer Res. 2017 Nov 01; 23(21):6629-6639.
    View in: PubMed
    Score: 0.115
  2. Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. Cancer Res. 2014 Feb 01; 74(3):765-74.
    View in: PubMed
    Score: 0.089
  3. Restoration of the molecular clock is tumor suppressive in neuroblastoma. Nat Commun. 2021 06 28; 12(1):4006.
    View in: PubMed
    Score: 0.038
  4. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia. 2021 06; 23(6):624-633.
    View in: PubMed
    Score: 0.037
  5. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis. Cell Death Dis. 2015 Aug 06; 6:e1841.
    View in: PubMed
    Score: 0.025
  6. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis. 2011 Sep; 14(3):255-66.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.